Treatment of adult short bowel syndrome patients with teduglutide

Bibliography

• Messing B, Pigot F, Rongier M, Intestinal absorption of free oral hyperalimentation in the very short bowel syndrome. Gastroenterology 1991;13:1502-8
   Google Scholar
• Jeppesen PB, Mortensen PB. Intestinal failure defined by measurements of intestinal energy and wet weight absorption. Gut 2000;46:701-6
   PubMed Web of Science ®Google Scholar
• Fleming CR, Remington M. Intestinal failure. In: Hill GL, editor. Nutrition and the surgical patient. Churchill Livingstone; New York: 1981. p. 219-35
   Google Scholar
• O'Keefe SJ, Buchman AL, Fishbein TM, Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 2006;4:6-10
   PubMed Web of Science ®Google Scholar
• Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003;124:1111-34
   PubMed Web of Science ®Google Scholar
• Nightingale JM, Lennard Jones JE. The short bowel syndrome: what's new and old? Dig Dis 1993;11:12-31
   PubMed Web of Science ®Google Scholar
• Messing B, Crenn P, Beau P, Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology 1999;117:1043-50
   PubMed Web of Science ®Google Scholar
• Goulet O, Joly F, Corriol O, Some new insights in intestinal failure-associated liver disease. Curr Opin Organ Transplant 2009;14:256-61
   PubMed Web of Science ®Google Scholar
• Lauverjat M, Hadj AA, Vanhems P, Chronic dehydration may impair renal function in patients with chronic intestinal failure on long-term parenteral nutrition. Clin Nutr 2006;25:75-81
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Langholz E, Mortensen PB. Quality of life in patients receiving home parenteral nutrition. Gut 1999;44:844-52
   PubMed Web of Science ®Google Scholar
• Baxter JP, Fayers PM, McKinlay AW. A review of the quality of life of adult patients treated with long-term parenteral nutrition. Clin Nutr 2006;25:543-53
   PubMed Web of Science ®Google Scholar
• Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive organ in patients with short bowel. Lancet 1994;343:373-6
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Mortensen PB. The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection. Gut 1998;43:478-83
   PubMed Web of Science ®Google Scholar
• Heydorn S, Jeppesen PB, Mortensen PB. Bile acid replacement therapy with cholylsarcosine for short bowel syndrome. Scand J Gastroenterol 1999;34:818-23
   PubMed Web of Science ®Google Scholar
• Joly F, Dray X, Corcos O, Tube feeding improves intestinal absorption in short bowel syndrome patients. Gastroenterology 2009;136:824-31
   PubMed Web of Science ®Google Scholar
• Nightingale JM, Lennard Jones JE, Walker ER, Oral salt supplements to compensate for jejunostomy losses: comparison of sodium chloride capsules, glucose electrolyte solution, and glucose polymer electrolyte solution. Gut 1992;33:759-61
   PubMed Web of Science ®Google Scholar
• Newton CR. Effect of codeine phosphate, lomotil, and isogel on ileostomy function. Gut 1978;19:377-83
   PubMed Web of Science ®Google Scholar
• Tytgat GN, Huibregtse K. Loperamide and ileostomy output – placebo-controled double-blind crossover study. Br Med J 1975;2:667-8
   PubMed Web of Science ®Google Scholar
• King RF, Norton T, Hill GL. A double-blind crossover study of the effect of loperamide hydrochloride and codeine phosphate on ileostomy output. Aust NZ J Surg 1982;52:121-4
   PubMedGoogle Scholar
• Cortot A, Fleming CR, Malagelada JR. Improved nutrient absorption after cimetidine in short-bowel syndrome with gastric hypersecretion. N Engl J Med 1979;300:79-80
   PubMed Web of Science ®Google Scholar
• Jacobsen O, Ladefoged K, Stage JG, Effects of cimetidine on jejunostomy effluents in patients with severe short-bowel syndrome. Scand J Gastroenterol 1986;21:824-8
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Staun M, Tjellesen L, Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. Gut 1998;43:763-9
   PubMed Web of Science ®Google Scholar
• Cooper JC, Williams NS, King RF, Effects of a long-acting somatostatin analogue in patients with severe ileostomy diarrhoea. Br J Surg 1986;73:128-31
   PubMed Web of Science ®Google Scholar
• Rodrigues CA, Lennard Jones JE, Thompson DG, The effects of octreotide, soy polysaccharide, codeine and loperamide on nutrient, fluid and electrolyte absorption in the short-bowel syndrome. Aliment Pharmacol Ther 1989;3:159-69
   PubMedGoogle Scholar
• Ladefoged K, Christensen KC, Hegnhoj J, Effect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome. Gut 1989;30:943-9
   PubMed Web of Science ®Google Scholar
• O'Keefe SJ, Peterson ME, Fleming CR. Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome. JPEN J Parenter Enteral Nutr 1994;18:26-34
   PubMed Web of Science ®Google Scholar
• Jeppesen PB. Growth factors in short-bowel syndrome patients. Gastroenterol Clin North Am 2007;36:109-21. vii
   PubMedGoogle Scholar
• Howard L. Home parenteral nutrition: survival, cost, and quality of life. Gastroenterology 2006;130:S52-9
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Erlich P, Asa SL, Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996;93:7911-16
   PubMed Web of Science ®Google Scholar
• Wojdemann M, Wettergren A, Hartmann B, Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998;33:828-32
   PubMed Web of Science ®Google Scholar
• Wojdemann M, Wettergren A, Hartmann B, Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999;84:2513-17
   PubMed Web of Science ®Google Scholar
• Guan X, Karpen HE, Stephens J, GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006;130:150-64
   PubMed Web of Science ®Google Scholar
• Bremholm L, Hornum M, Henriksen BM, Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 2009;44:314-19
   PubMed Web of Science ®Google Scholar
• Bremholm L, Hornum M, Andersen UB, The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept 2011;168:32-8
   PubMedGoogle Scholar
• Cani PD, Possemiers S, Van de WT, Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58:1091-103
   PubMed Web of Science ®Google Scholar
• Brubaker PL, Izzo A, Hill M, Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 1997;272:E1050-8
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Hartmann B, Thulesen J, Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001;120:806-15
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Lund P, Gottschalck IB, Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009;2009:616054
   PubMed Web of Science ®Google Scholar
• Ivory CP, Wallace LE, McCafferty DM, Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2008;295:G1202-10
   PubMed Web of Science ®Google Scholar
• Sigalet DL, Wallace LE, Holst JJ, Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007;293:G211-21
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Hartmann B, Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009;45:833-42
   PubMed Web of Science ®Google Scholar
• Munroe DG, Gupta AK, Kooshesh F, Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999;96:1569-73
   PubMed Web of Science ®Google Scholar
• Dube PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007;293:E460-5
   PubMed Web of Science ®Google Scholar
• Yusta B, Huang L, Munroe D, Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000;119:744-55
   PubMed Web of Science ®Google Scholar
• Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 2001;98:12497-502
   PubMed Web of Science ®Google Scholar
• Orskov C, Hartmann B, Poulsen SS, GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005;124:105-12
   PubMed Web of Science ®Google Scholar
• Bahrami J, Yusta B, Drucker DJ. ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel. Gastroenterology 2010;138:2447-56
   PubMed Web of Science ®Google Scholar
• Marier JF, Beliveau M, Mouksassi MS, Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol 2008;48:1289-99
   PubMed Web of Science ®Google Scholar
• Marier JF, Mouksassi MS, Gosselin NH, Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. J Clin Pharmacol 2010;50:36-49
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Sanguinetti EL, Buchman A, Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005;54:1224-31
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Gilroy R, Pertkiewicz M, Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011;60:902-14
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Hartmann B, Hansen BS, Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 1999;45:559-63
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Hartmann B, Thulesen J, Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000;47:370-6
   PubMed Web of Science ®Google Scholar
• Compher C, Gilroy R, Pertkiewicz M, Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome. JPEN J Parenter Enteral Nutr 2011;35:603-9
   PubMedGoogle Scholar
• Thulesen J, Hartmann B, Hare KJ, Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004;53:1145-50
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceuticals International Media homepage. Available from: http://www.nycomed.com/media/news-releases/2011/nycomed-submits-european-marketing-authorisation-application-for-teduglutide–-revestive/ [last access December 22 2011]
   Google Scholar
• Drug Information Online. Available from: http://www.drugs.com/clinical_trials/gattex-teduglutide-shown-reduce-parenteral-support-volume-patients-adult-short-bowel-syndrome-11724.html [last access December 22 2011]
   Google Scholar